ANDREW PETER WILLIAM,LONNEN RANA,DAMASO MAFALDA PIRES,FRICKEL FRITZ-FRIEDER,HIRST SIMON CHRISTOPHER,DAVIES MARK WILLIAM,HAMZA DANIEL
申请号：
NZ62563612
公开号：
NZ625636A
申请日:
2012.12.05
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The disclosure relates to pyrrole derivative compounds of formula (I) which are cytolysin inhibitors, wherein R1, R2, R3, R4a and R4b are as defined in the specification. These compounds are suitable for use in the treatment of bacterial infections caused by bacteria selected from Streptococcus spp. (e.g. Streptococcus pneumoniae, Group A Streptococci or Streptococcus suis), Clostridium spp. (e.g. Clostridium perfringens), Listeria spp. (e.g. Listeria monocytogenes) or Bacillus spp. (e.g. Bacillus anthracis) which produce pore-forming toxins, such as cholesterol dependent cytolysins. These compounds are also suitable for the treatment of conditions selected from gas gangrene, gastrointestinal anthrax, inhalational anthrax, porcine meningitis, encephalitis, septicaemia/bacteraemia and pneumonia which are caused by bacteria other than pneumococcus.
